Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Anaplastic Large Cell Lymphoma: early-phase trial registry
5 of 26 indexed Anaplastic Large Cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #627 of 28,707 conditions by registered trial count.
26 US clinical trials · 5 currently recruiting · #627 of 28,707 conditions by registered trial count
Anaplastic Large Cell Lymphoma: 26 US clinical trials tracked, 5 recruiting.
Anaplastic Large Cell Lymphoma is the subject of 26 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 6 of these trials.
Enrollment posture brief
Registry condition anaplastic-large-cell-lymphoma
OPEN 5 | RECR 19% | LATE 0 | EARLY 25 | RANK #627 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Gingivitis (19% recruiting · 26 trials)
Anaplastic Large Cell Lymphoma lists 5 open slots (19% of 26 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Anaplastic Large Cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Anaplastic Large Cell Lymphoma is recruiting below its size-band peers.
5 of 26 indexed trials (19.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Anaplastic Large Cell Lymphoma research.
National Cancer Institute (NCI) accounts for 6 of 26 trials (23.1%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Anaplastic Large Cell Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 26 trials that report a genuine target (sentinel values excluded). 23 of those (88.5%) plan for fewer than 100 participants.
-
Anaplastic Large Cell Lymphoma research is mostly interventional.
26 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
26 total, page 1 of 1
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
NCT04195633
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
National Cancer Institute (NCI)
NCT07055477
A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
Memorial Sloan Kettering Cancer Center
NCT07001384
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Mayo Clinic
NCT06508463
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
National Cancer Institute (NCI)
NCT07388563
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
Mayo Clinic
NCT01787409
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
Northwestern University
NCT02232516
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
Tessa Therapeutics
NCT04526834
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
City of Hope Medical Center
NCT03598998
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Washington University School of Medicine
NCT05377827
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Mayo Clinic
NCT00918333
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
NCT00073918
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
University of Chicago
NCT01839916
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
National Cancer Institute (NCI)
NCT01258998
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Massachusetts General Hospital
NCT00644189
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
National Cancer Institute (NCI)
NCT01326702
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
NCT01261247
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant
Case Comprehensive Cancer Center
NCT01959477
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
University of Washington
NCT00601718
Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Xencor
NCT00606645
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
Fred Hutchinson Cancer Center
NCT00006251
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
Case Comprehensive Cancer Center
NCT01658319
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
University of Nebraska
NCT01336920
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
NCT00131937
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
NCT00769288
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Pierluigi Porcu
NCT01129180
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 2 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Anaplastic Large Cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Anaplastic Large Cell Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Anaplastic Large Cell Lymphoma page
26 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Anaplastic Large Cell Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Anaplastic Large Cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Anaplastic Large Cell Lymphoma condition card totals 26 registered trials; most-linked intervention laboratory biomarker analysis; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.